 Timothy Garrington
Concepts (315)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Central Nervous System Neoplasms | 2 | 2024 | 149 | 0.720 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 64 | 0.590 |
Why?
| | Sarcoma, Ewing | 3 | 2025 | 87 | 0.580 |
Why?
| | MAP Kinase Kinase Kinases | 6 | 2004 | 70 | 0.530 |
Why?
| | Mitogen-Activated Protein Kinases | 8 | 2004 | 312 | 0.420 |
Why?
| | Hodgkin Disease | 2 | 2016 | 133 | 0.390 |
Why?
| | Kidney Neoplasms | 3 | 2021 | 347 | 0.340 |
Why?
| | Neuroblastoma | 3 | 2017 | 151 | 0.340 |
Why?
| | Neoplasms | 6 | 2025 | 2454 | 0.320 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 4 | 2004 | 131 | 0.310 |
Why?
| | Beckwith-Wiedemann Syndrome | 1 | 2008 | 6 | 0.310 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2014 | 83 | 0.310 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2009 | 128 | 0.300 |
Why?
| | Asparaginase | 2 | 1998 | 29 | 0.290 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2008 | 55 | 0.290 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 282 | 0.290 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 5 | 2004 | 161 | 0.290 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2008 | 60 | 0.280 |
Why?
| | MAP Kinase Kinase Kinase 1 | 3 | 2005 | 19 | 0.280 |
Why?
| | Histiocytosis, Langerhans-Cell | 2 | 2020 | 36 | 0.270 |
Why?
| | Pancreatitis | 2 | 1998 | 129 | 0.270 |
Why?
| | Child | 23 | 2025 | 20962 | 0.250 |
Why?
| | MAP Kinase Kinase Kinase 2 | 7 | 2012 | 12 | 0.250 |
Why?
| | Mast Cells | 3 | 2003 | 142 | 0.250 |
Why?
| | Adaptor Proteins, Signal Transducing | 4 | 2003 | 399 | 0.240 |
Why?
| | Testicular Neoplasms | 2 | 2017 | 102 | 0.240 |
Why?
| | Child, Preschool | 17 | 2021 | 10522 | 0.240 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 58 | 0.230 |
Why?
| | Clonal Evolution | 1 | 2025 | 39 | 0.230 |
Why?
| | Appointments and Schedules | 1 | 2025 | 85 | 0.230 |
Why?
| | Medical Errors | 1 | 2025 | 108 | 0.220 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2004 | 85 | 0.220 |
Why?
| | Catheterization, Central Venous | 1 | 2025 | 104 | 0.210 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 70 | 0.210 |
Why?
| | Central Nervous System Diseases | 1 | 2024 | 69 | 0.210 |
Why?
| | Lung Neoplasms | 2 | 2021 | 2344 | 0.200 |
Why?
| | MAP Kinase Signaling System | 3 | 2008 | 314 | 0.200 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 106 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2025 | 229 | 0.200 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 274 | 0.200 |
Why?
| | Parental Leave | 1 | 2022 | 24 | 0.200 |
Why?
| | Adolescent | 18 | 2025 | 20451 | 0.200 |
Why?
| | Anemia | 1 | 2023 | 162 | 0.190 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 182 | 0.190 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2511 | 0.180 |
Why?
| | Thrombocytopenia | 1 | 2023 | 189 | 0.180 |
Why?
| | Sarcoma | 2 | 2015 | 175 | 0.180 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.180 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 82 | 0.180 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1161 | 0.180 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 28 | 0.180 |
Why?
| | Stem Cell Factor | 1 | 2000 | 14 | 0.180 |
Why?
| | Pituitary Diseases | 1 | 2020 | 21 | 0.180 |
Why?
| | Ribonuclease III | 1 | 2021 | 37 | 0.170 |
Why?
| | Receptors, IgE | 1 | 2000 | 44 | 0.170 |
Why?
| | Cholestasis | 1 | 2023 | 232 | 0.170 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2020 | 8 | 0.170 |
Why?
| | Fibroblasts | 3 | 2005 | 954 | 0.170 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2020 | 20 | 0.170 |
Why?
| | DEAD-box RNA Helicases | 1 | 2021 | 66 | 0.170 |
Why?
| | Pituitary Gland | 1 | 2020 | 148 | 0.170 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 29 | 0.170 |
Why?
| | Survival Rate | 3 | 2019 | 1872 | 0.160 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 279 | 0.160 |
Why?
| | Humans | 37 | 2025 | 129847 | 0.150 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 210 | 0.150 |
Why?
| | Disease-Free Survival | 2 | 2019 | 647 | 0.150 |
Why?
| | Infant | 11 | 2020 | 9018 | 0.150 |
Why?
| | Polycystic Kidney Diseases | 1 | 2019 | 68 | 0.150 |
Why?
| | Octreotide | 1 | 1998 | 27 | 0.140 |
Why?
| | Female | 22 | 2025 | 68829 | 0.140 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 265 | 0.140 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2017 | 13 | 0.140 |
Why?
| | Abdominal Neoplasms | 1 | 2017 | 34 | 0.140 |
Why?
| | Cancer Survivors | 1 | 2022 | 257 | 0.140 |
Why?
| | Cytodiagnosis | 1 | 2017 | 32 | 0.130 |
Why?
| | Frozen Sections | 1 | 2017 | 26 | 0.130 |
Why?
| | Seminoma | 1 | 2017 | 18 | 0.130 |
Why?
| | Wilms Tumor | 1 | 2018 | 78 | 0.130 |
Why?
| | Quality Improvement | 1 | 2025 | 1112 | 0.130 |
Why?
| | Male | 21 | 2025 | 63759 | 0.130 |
Why?
| | Interferon-gamma | 1 | 2020 | 773 | 0.130 |
Why?
| | Cytokines | 2 | 2004 | 2022 | 0.130 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2003 | 1205 | 0.130 |
Why?
| | Protein Processing, Post-Translational | 1 | 1999 | 457 | 0.130 |
Why?
| | Enzyme Activation | 6 | 2004 | 813 | 0.130 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1999 | 383 | 0.120 |
Why?
| | Health Planning | 1 | 2015 | 46 | 0.120 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 482 | 0.120 |
Why?
| | Mediastinal Neoplasms | 1 | 2014 | 39 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2271 | 0.110 |
Why?
| | Transcription Factor AP-1 | 2 | 2005 | 88 | 0.110 |
Why?
| | Thoracoscopy | 1 | 2014 | 54 | 0.110 |
Why?
| | Transition to Adult Care | 1 | 2015 | 82 | 0.110 |
Why?
| | Disease Management | 2 | 2015 | 592 | 0.110 |
Why?
| | Xanthogranuloma, Juvenile | 1 | 2013 | 5 | 0.110 |
Why?
| | Carrier Proteins | 4 | 2003 | 741 | 0.110 |
Why?
| | Arabinonucleosides | 1 | 2013 | 8 | 0.110 |
Why?
| | Adenine Nucleotides | 1 | 2013 | 22 | 0.110 |
Why?
| | Biopsy | 1 | 2017 | 1089 | 0.110 |
Why?
| | Histiocytosis, Sinus | 1 | 2013 | 7 | 0.110 |
Why?
| | Retrospective Studies | 7 | 2024 | 14553 | 0.100 |
Why?
| | Ambulatory Care Facilities | 1 | 2015 | 228 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1368 | 0.100 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 91 | 0.100 |
Why?
| | Salvage Therapy | 1 | 2013 | 136 | 0.100 |
Why?
| | Heart Diseases | 1 | 2016 | 352 | 0.100 |
Why?
| | Prognosis | 5 | 2025 | 3773 | 0.100 |
Why?
| | Prevalence | 1 | 2019 | 2564 | 0.100 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2012 | 145 | 0.100 |
Why?
| | Anesthesia | 1 | 2014 | 172 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 326 | 0.090 |
Why?
| | Gene Expression Regulation | 4 | 2012 | 2545 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor | 2 | 2002 | 161 | 0.090 |
Why?
| | Signal Transduction | 3 | 2004 | 4935 | 0.090 |
Why?
| | Program Development | 2 | 2015 | 355 | 0.090 |
Why?
| | Ventricular Remodeling | 1 | 2012 | 256 | 0.080 |
Why?
| | Stem Cells | 2 | 2008 | 578 | 0.080 |
Why?
| | Pediatrics | 2 | 2008 | 1074 | 0.080 |
Why?
| | Laparoscopy | 1 | 2014 | 447 | 0.080 |
Why?
| | Subtraction Technique | 1 | 2009 | 23 | 0.080 |
Why?
| | Primary Health Care | 2 | 2022 | 1687 | 0.080 |
Why?
| | Radiopharmaceuticals | 1 | 2009 | 168 | 0.080 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2008 | 50 | 0.070 |
Why?
| | Myocytes, Cardiac | 1 | 2012 | 499 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1033 | 0.070 |
Why?
| | Heart Ventricles | 1 | 2012 | 781 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 1998 | 2045 | 0.070 |
Why?
| | Infant, Newborn | 4 | 2023 | 5772 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2012 | 636 | 0.070 |
Why?
| | Embryo, Mammalian | 2 | 2005 | 224 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 4 | 2012 | 21 | 0.060 |
Why?
| | Adult | 6 | 2019 | 35634 | 0.060 |
Why?
| | Risk Assessment | 1 | 2015 | 3269 | 0.060 |
Why?
| | Leukemia | 1 | 2008 | 230 | 0.060 |
Why?
| | Young Adult | 6 | 2018 | 12467 | 0.060 |
Why?
| | Age Factors | 3 | 2018 | 3161 | 0.060 |
Why?
| | Near Miss, Healthcare | 1 | 2025 | 10 | 0.060 |
Why?
| | Hypoxia | 1 | 2012 | 1087 | 0.060 |
Why?
| | Epidermal Growth Factor | 2 | 2003 | 170 | 0.060 |
Why?
| | Cell Line | 5 | 2003 | 2780 | 0.060 |
Why?
| | Acute Disease | 2 | 1998 | 980 | 0.060 |
Why?
| | Transcription Factors | 2 | 2021 | 1645 | 0.060 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 179 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2005 | 52 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2008 | 426 | 0.060 |
Why?
| | SEER Program | 2 | 2016 | 202 | 0.060 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 70 | 0.060 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2005 | 99 | 0.060 |
Why?
| | Phosphorylation | 3 | 2012 | 1716 | 0.060 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2004 | 28 | 0.060 |
Why?
| | Apoptosis | 3 | 2002 | 2489 | 0.050 |
Why?
| | Genes, jun | 1 | 2003 | 9 | 0.050 |
Why?
| | Blotting, Western | 2 | 2004 | 1204 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1271 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 610 | 0.050 |
Why?
| | Myogenic Regulatory Factors | 1 | 2003 | 58 | 0.050 |
Why?
| | DNA Methylation | 1 | 2008 | 606 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2004 | 377 | 0.050 |
Why?
| | Tissue Donors | 1 | 2005 | 391 | 0.050 |
Why?
| | Macromolecular Substances | 2 | 2003 | 216 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 426 | 0.050 |
Why?
| | Animals | 9 | 2012 | 35409 | 0.050 |
Why?
| | Mice | 6 | 2012 | 16983 | 0.050 |
Why?
| | Promoter Regions, Genetic | 3 | 2005 | 1213 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2012 | 2888 | 0.050 |
Why?
| | src-Family Kinases | 1 | 2003 | 95 | 0.050 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 279 | 0.050 |
Why?
| | Recurrence | 3 | 2013 | 1013 | 0.050 |
Why?
| | Survivors | 2 | 2016 | 464 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2000 | 1900 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2025 | 483 | 0.050 |
Why?
| | Databases, Factual | 2 | 2018 | 1269 | 0.050 |
Why?
| | Central Nervous System | 1 | 2024 | 256 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2005 | 4102 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 836 | 0.050 |
Why?
| | Survivorship | 1 | 2022 | 47 | 0.050 |
Why?
| | Mutation | 3 | 2020 | 3706 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2008 | 431 | 0.050 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 24 | 0.050 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 24 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 627 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2005 | 1416 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1897 | 0.040 |
Why?
| | Kidney Diseases, Cystic | 1 | 2021 | 21 | 0.040 |
Why?
| | Curriculum | 1 | 2007 | 928 | 0.040 |
Why?
| | Receptor Aggregation | 1 | 2000 | 10 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2021 | 92 | 0.040 |
Why?
| | Pneumothorax | 1 | 2021 | 38 | 0.040 |
Why?
| | Reoviridae | 1 | 2000 | 37 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2020 | 27 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2021 | 140 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 338 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5437 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2000 | 363 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2000 | 277 | 0.040 |
Why?
| | Mating Factor | 1 | 1999 | 3 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4896 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 201 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1999 | 52 | 0.040 |
Why?
| | Receptors, Growth Factor | 1 | 1999 | 55 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1327 | 0.040 |
Why?
| | Growth Substances | 1 | 1999 | 148 | 0.040 |
Why?
| | Insect Proteins | 1 | 1999 | 37 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 634 | 0.040 |
Why?
| | TRPP Cation Channels | 1 | 2019 | 79 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2000 | 366 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 443 | 0.040 |
Why?
| | Fungal Proteins | 1 | 1999 | 130 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 494 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1686 | 0.040 |
Why?
| | MAP Kinase Kinase 5 | 3 | 2003 | 4 | 0.040 |
Why?
| | Chronic Disease | 2 | 2015 | 1724 | 0.040 |
Why?
| | Cytoskeleton | 1 | 1999 | 184 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2000 | 477 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 851 | 0.040 |
Why?
| | Dexamethasone | 1 | 2020 | 352 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1441 | 0.030 |
Why?
| | United States | 3 | 2022 | 13913 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1201 | 0.030 |
Why?
| | Mammals | 1 | 1999 | 274 | 0.030 |
Why?
| | Drosophila melanogaster | 1 | 1999 | 211 | 0.030 |
Why?
| | Incidence | 1 | 2024 | 2646 | 0.030 |
Why?
| | Receptors, Cell Surface | 1 | 2019 | 381 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1042 | 0.030 |
Why?
| | Hepatoblastoma | 1 | 2017 | 42 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2017 | 55 | 0.030 |
Why?
| | Microtubules | 1 | 1999 | 264 | 0.030 |
Why?
| | Teratoma | 1 | 2017 | 103 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 482 | 0.030 |
Why?
| | Stress, Physiological | 1 | 1999 | 412 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2016 | 50 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 1999 | 296 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 6550 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 1999 | 530 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 577 | 0.030 |
Why?
| | Neurilemmoma | 1 | 2014 | 23 | 0.030 |
Why?
| | Organizational Innovation | 1 | 2015 | 139 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 187 | 0.030 |
Why?
| | Parents | 1 | 2022 | 1319 | 0.030 |
Why?
| | Peptides | 1 | 1999 | 926 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3089 | 0.030 |
Why?
| | Lymphoma | 1 | 2014 | 198 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1282 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2000 | 2703 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 1989 | 0.020 |
Why?
| | MAP Kinase Kinase 7 | 2 | 2003 | 7 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2000 | 1937 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1291 | 0.020 |
Why?
| | Two-Hybrid System Techniques | 2 | 2003 | 55 | 0.020 |
Why?
| | Colorado | 2 | 2015 | 4410 | 0.020 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2002 | 29 | 0.020 |
Why?
| | fas Receptor | 2 | 2002 | 94 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 878 | 0.020 |
Why?
| | Caspases | 2 | 2002 | 245 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2020 | 10241 | 0.020 |
Why?
| | Aged | 2 | 2022 | 22107 | 0.020 |
Why?
| | Transfection | 2 | 2003 | 918 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2012 | 505 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 713 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2008 | 64 | 0.020 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2008 | 107 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1274 | 0.020 |
Why?
| | Drug Design | 1 | 2008 | 158 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 277 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2014 | 879 | 0.020 |
Why?
| | Schools, Medical | 1 | 2007 | 136 | 0.020 |
Why?
| | Clinical Clerkship | 1 | 2007 | 96 | 0.020 |
Why?
| | Medical Oncology | 1 | 2008 | 268 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 528 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2005 | 121 | 0.020 |
Why?
| | Protein Binding | 2 | 2003 | 2123 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 7158 | 0.020 |
Why?
| | Middle Aged | 2 | 2017 | 31177 | 0.010 |
Why?
| | Fos-Related Antigen-2 | 1 | 2005 | 1 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 49 | 0.010 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2005 | 29 | 0.010 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2005 | 149 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 7066 | 0.010 |
Why?
| | Dimerization | 1 | 2005 | 193 | 0.010 |
Why?
| | Faculty, Medical | 1 | 2007 | 269 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 402 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2008 | 1160 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 1005 | 0.010 |
Why?
| | MEF2 Transcription Factors | 1 | 2003 | 62 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 240 | 0.010 |
Why?
| | Mink | 1 | 2003 | 12 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 167 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 215 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4077 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1501 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2005 | 590 | 0.010 |
Why?
| | Caspase 3 | 1 | 2002 | 244 | 0.010 |
Why?
| | Models, Biological | 1 | 2008 | 1724 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2142 | 0.010 |
Why?
| | MAP Kinase Kinase Kinase 3 | 1 | 2000 | 4 | 0.010 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2000 | 9 | 0.010 |
Why?
| | Caspase 8 | 1 | 2000 | 48 | 0.010 |
Why?
| | Caspase 9 | 1 | 2000 | 56 | 0.010 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2000 | 44 | 0.010 |
Why?
| | COS Cells | 1 | 2000 | 186 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2002 | 362 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 2000 | 151 | 0.010 |
Why?
| | Caspase Inhibitors | 1 | 2000 | 81 | 0.010 |
Why?
| | Oxidants | 1 | 2000 | 109 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2002 | 434 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2833 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2000 | 182 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1560 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2000 | 317 | 0.010 |
Why?
| | Mitosis | 1 | 1999 | 180 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2003 | 1063 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2000 | 1110 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2003 | 1264 | 0.010 |
Why?
| | Kidney | 1 | 2003 | 1383 | 0.010 |
Why?
|
|
Garrington's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|